Clinical Implications of Prospective Genomic Profiling of Metastatic Breast Cancer Patients

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2020 Aug 20

PMID 32811538

Citations 23

Authors

Courtney T van Geelen

Peter Savas

Zhi Ling Teo

Stephen J Luen

Chen-Fang Weng

Yi-An Ko

Keilly S Kuykhoven

Franco Caramia

Roberto Salgado

Prudence A Francis

Sarah-Jane Dawson

Stephen B Fox

Andrew Fellowes

Sherene Loi

Affiliations

Soon will be listed here.

Abstract

Background: Metastatic breast cancer remains incurable. Next-generation sequencing (NGS) offers the ability to identify actionable genomic alterations in tumours which may then be matched with targeted therapies, but the implementation and utility of this approach is not well defined for patients with metastatic breast cancer.

Methods: We recruited patients with advanced breast cancer of any subtype for prospective targeted NGS of their most recent tumour samples, using a panel of 108 breast cancer-specific genes. Genes were classified as actionable or non-actionable using the European Society of Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT) guidelines.

Results: Between February 2014 and May 2019, 322 patients were enrolled onto the study, with 72% (n = 234) of patients successfully sequenced (n = 357 samples). The majority (74%, n = 171) of sequenced patients were found to carry a potentially actionable alteration, the most common being a PIK3CA mutation. Forty-three percent (n = 74) of patients with actionable alterations were referred for a clinical trial or referred for confirmatory germline testing or had a change in therapy outside of clinical trials. We found alterations in AKT1, BRCA2, CHEK2, ESR1, FGFR1, KMT2C, NCOR1, PIK3CA and TSC2 to be significantly enriched in our metastatic population compared with primary breast cancers. Concordance between primary and metastatic samples for key driver genes (TP53, ERBB2 amplification) was > 75%. Additionally, we found that patients with a higher number of mutations had a significantly worse overall survival.

Conclusion: Genomic profiling of patients with metastatic breast cancer can have clinical implications and should be considered in all suitable patients.

Citing Articles

ctDNA-based liquid biopsy reveals wider mutational profile with therapy resistance and metastasis susceptibility signatures in early-stage breast cancer patients.

Bharde A, Nadagouda S, Dongare M, Hariramani K, Basavalingegowda M, Haldar S J Liq Biopsy. 2025; 7:100284.

PMID: 40027235 PMC: 11863978. DOI: 10.1016/j.jlb.2024.100284.

Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials.

Luen S, Brown L, van Geelen C, Savas P, Kammler R, DellOrto P JCO Precis Oncol. 2025; 9:e2400599.

PMID: 39854658 PMC: 11835511. DOI: 10.1200/PO-24-00599.

New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer-Current State and Molecular Pathology Perspective.

Liu L, Graff S, Wang Y Cancers (Basel). 2025; 17(1.

PMID: 39796647 PMC: 11718791. DOI: 10.3390/cancers17010016.

Sustained lymphocyte decreases after treatment for early breast cancer.

Dixon-Douglas J, Virassamy B, Clarke K, Hun M, Luen S, Savas P NPJ Breast Cancer. 2024; 10(1):94.

PMID: 39433772 PMC: 11493948. DOI: 10.1038/s41523-024-00698-4.

The modification role and tumor association with a methyltransferase: KMT2C.

Jiao Y, Lv Y, Liu M, Liu Y, Han M, Xiong X Front Immunol. 2024; 15:1444923.

PMID: 39165358 PMC: 11333232. DOI: 10.3389/fimmu.2024.1444923.

References

Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H . Precision medicine for metastatic breast cancer--limitations and solutions. Nat Rev Clin Oncol. 2015; 12(12):693-704. DOI: 10.1038/nrclinonc.2015.123. View

El Sayed R, Jamal L, Iskandarani S, Kort J, Abdel Salam M, Assi H . Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials. Front Oncol. 2019; 9:510. PMC: 6597942. DOI: 10.3389/fonc.2019.00510. View

Rivenbark A, OConnor S, Coleman W . Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J Pathol. 2013; 183(4):1113-1124. PMC: 5691324. DOI: 10.1016/j.ajpath.2013.08.002. View

Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R . A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. Oncologist. 2014; 19(5):453-8. PMC: 4012963. DOI: 10.1634/theoncologist.2013-0377. View

Yates L, Knappskog S, Wedge D, Farmery J, Gonzalez S, Martincorena I . Genomic Evolution of Breast Cancer Metastasis and Relapse. Cancer Cell. 2017; 32(2):169-184.e7. PMC: 5559645. DOI: 10.1016/j.ccell.2017.07.005. View

Basho R, Gagliato D, Ueno N, Wathoo C, Chen H, Shariati M . Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 2016; 7(47):76362-76373. PMC: 5363515. DOI: 10.18632/oncotarget.12987. View

Bertucci F, Ng C, Patsouris A, Droin N, Piscuoglio S, Carbuccia N . Genomic characterization of metastatic breast cancers. Nature. 2019; 569(7757):560-564. DOI: 10.1038/s41586-019-1056-z. View

Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria J . Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. PLoS Med. 2016; 13(12):e1002201. PMC: 5189935. DOI: 10.1371/journal.pmed.1002201. View

Salgado R, Loi S . Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance. Lancet Oncol. 2017; 19(1):3-5. DOI: 10.1016/S1470-2045(17)30905-1. View

10.

Condorelli R, Mosele F, Verret B, Bachelot T, Bedard P, Cortes J . Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2019; 30(3):365-373. DOI: 10.1093/annonc/mdz036. View

11.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G . The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014; 26(2):259-71. PMC: 6267863. DOI: 10.1093/annonc/mdu450. View

12.

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

13.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

14.

Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R . VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016; 44(11):e108. PMC: 4914105. DOI: 10.1093/nar/gkw227. View

15.

Wang K, Li M, Hakonarson H . ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38(16):e164. PMC: 2938201. DOI: 10.1093/nar/gkq603. View

16.

Kuilman T, Velds A, Kemper K, Ranzani M, Bombardelli L, Hoogstraat M . CopywriteR: DNA copy number detection from off-target sequence data. Genome Biol. 2015; 16:49. PMC: 4396974. DOI: 10.1186/s13059-015-0617-1. View

17.

Auton A, Brooks L, Durbin R, Garrison E, Kang H, Korbel J . A global reference for human genetic variation. Nature. 2015; 526(7571):68-74. PMC: 4750478. DOI: 10.1038/nature15393. View

18.

Robinson J, Thorvaldsdottir H, Winckler W, Guttman M, Lander E, Getz G . Integrative genomics viewer. Nat Biotechnol. 2011; 29(1):24-6. PMC: 3346182. DOI: 10.1038/nbt.1754. View

19.

Landrum M, Lee J, Benson M, Brown G, Chao C, Chitipiralla S . ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2017; 46(D1):D1062-D1067. PMC: 5753237. DOI: 10.1093/nar/gkx1153. View

20.

Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View